The biological differences between ovarian serous carcinoma and diffuse peritoneal malignant mesothelioma

Seminars in Diagnostic Pathology

Volumn 23, Issue 1, 2006, Pages 35-43

  Davidson, Ben ^a   Risberg, Björn ^a   Berner, Aasmund ^a   Bedrossian, Carlos W M ^b   Reich, Reuven ^c  

^a UNIVERSITY OF OSLO   (Norway)

^b Norwegian American Hospital   (United States)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Effusions; Malignant mesothelioma; Metastasis; Ovarian carcinoma

Indexed keywords

ALPHA6 INTEGRIN; ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; GELATINASE A; HEPARANASE; HLA G ANTIGEN; INTERLEUKIN 8; LAMININ RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NERVE GROWTH FACTOR RECEPTOR; PROTEIN P75; PROTEIN TYROSINE KINASE A; STRESS ACTIVATED PROTEIN KINASE; VASCULOTROPIN;

ARTICLE; CANCER GROWTH; CARCINOGENESIS; COMPARATIVE STUDY; CYSTADENOCARCINOMA; DISEASE COURSE; HUMAN; IMMUNOHISTOCHEMISTRY; MALIGNANT MESOTHELIOMA; MEDICAL DOCUMENTATION; OVARY CARCINOMA; PERITONEUM MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAMPLE SIZE; TISSUE SECTION; WESTERN BLOTTING;

CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33748943120     PISSN: 07402570     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semdp.2006.06.003     Document Type: Article

References (115)

1. Spirtas R., Connelly R.R., and Tucker M.A. Survival patterns for malignant mesothelioma: the SEER experience. Int J Cancer 41 (1988) 525-530
2. Sugarbaker P.H., Welch L.S., Mohamed F., and Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin North Am 12 (2003) 605-621
3. Antman K.H., Corson J.M., Li F.P., et al. Malignant mesothelioma following radiation exposure. J Clin Oncol 1 (1983) 695-700
4. Riddell R.H., Goodman M.J., and Moossa A.R. Peritoneal malignant mesothelioma in a patient with recurrent peritonitis. Cancer 48 (1981) 134-139
5. Maurer R., and Egloff B. Malignant peritoneal mesothelioma after cholangiography with thorotrast. Cancer 36 (1975) 1381-1385
6. Baker P.M., Clement P.B., and Young R.H. Malignant peritoneal mesothelioma in women: a study of 75 cases with emphasis on their morphologic spectrum and differential diagnosis. Am J Clin Pathol 123 (2005) 724-737
7. Park B.J., Alexander H.R., Libutti S.K., et al. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol 6 (1999) 582-590
8. Loggie B.W., Fleming R.A., McQuellon R.P., et al. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg 67 (2001) 999-1003
9. Kerrigan S.A., Tumnir R.T., Clement P.B., et al. Diffuse malignant epithelial mesotheliomas of the peritoneum in women: a clinicopathologic study of 25 patients. Cancer 94 (2002) 378-385
10. Feldman A.L., Libutti S.K., Pingpank J.F., et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 21 (2003) 4560-4567
11. Deraco M., Casali P., Inglese M.G., et al. Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. J Surg Oncol 83 (2003) 147-153
12. Janne P.A., Wozniak A.J., Belani C.P., et al. Open-label study of pemetrexed alone or in combination with Cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer 7 (2005) 40-46
13. Yan T.D., Haveric N., Carmignani C.P., et al. Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer 103 (2005) 839-849
14. Jemal A., Tiwari R.C., Murray T., et al. Cancer statistics, 2004. CA Cancer J Clin 54 (2004) 8-29
15. Davidson B., Risberg B., Reich R., et al. Effusion cytology in ovarian cancer: new molecular methods as aids to diagnosis and prognosis. Clin Lab Med 23 (2003) 729-754
16. See H.T., Kavanagh J.J., Hu W., et al. Targeted therapy for epithelial ovarian cancer: current status and future prospects. Int J Gynecol Cancer 13 (2003) 701-734
17. Bedrossian C.W.M. Malignant Effusions: A Multimodal Approach to Cytologic Diagnosis (1994), Igaku-Shoin, New York, NY
18. Bedrossian C.W.M. Diagnostic problems in serous effusions. Diagn Cytopathol 19 (1998) 131-137
19. Davidson B., Nielsen S., Christensen J., et al. The role of Desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol 25 (2001) 1405-1412
20. Ordonez N.G. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol 22 (1998) 1203-1214
21. Scharnhorst V., van der Eb A.J., and Jochemsen A.G. WT1 proteins: functions in growth and differentiation. Gene 273 (2001) 141-161
22. Kumar-Singh S., Segers K., Rodeck U., et al. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis. J Pathol 181 (1997) 67-74
23. Waldstrom M., and Grove A. Immunohistochemical expression of wilms tumor gene protein in different histologic subtypes of ovarian carcinomas. Arch Pathol Lab Med 129 (2005) 85-88
24. Drapkin R., Crum C.P., and Hecht J.L. Expression of candidate tumor markers in ovarian carcinoma and benign ovary: evidence for a link between epithelial phenotype and neoplasia. Hum Pathol 35 (2004) 1014-1021
25. Borczuk A.C., Taub R.N., Hesdorffer M., et al. P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma. Clin Cancer Res 11 (2005) 3303-3308
26. Barbacid M. Neurotrophic factors and their receptors. Curr Opin Cell Biol 7 (1995) 148-155
27. Kaplan D.R., and Miller F.D. Signal transduction by the neurotrophin receptors. Curr Opin Cell Biol 9 (1997) 213-221
28. Patapoutian A., and Reichardt L.F. Trk receptors: mediators of neurotrophin action. Curr Opin Neurobiol 11 (2001) 272-280
29. Barker P.A., Lomen-Hoerth C., Gensch E.M., et al. Tissue-specific alternative splicing generates two isoforms of the trkA receptor. J Biol Chem 268 (1993) 15150-15157
30. Weismann C., Ultsch M.H., Bass S.H., et al. Crystal structure of the nerve growth factor in complex with the ligand-binding domain of the TrkA receptor. Nature 401 (1999) 184-188
31. Greene L.A., and Kaplan D.R. Early events in neurotrophin signalling via Trk and p75 receptors. Curr Opin Neurobiol 5 (1995) 579-587
32. Kaplan D.R., and Miller F.D. Neutrophin signal transduction in the nervous system. Curr Opin Neurobiol 10 (2000) 381-391
33. Roux P.P., and Barker P.A. Neurotrophin signaling through the p75 neurotrophin receptor. Prog Neurobiol 67 (2002) 203-233
34. Nakagawara A. Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett 169 (2001) 107-114
35. Shibayama E., and Koizumi H. Cellular localization of the Trk neurotrophin receptor family in human non-neuronal tissues. Am J Pathol 148 (1996) 1807-1818
36. McGregor L.M., McCune B.K., Graff J.R., et al. Roles of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression. Proc Natl Acad Sci USA 96 (1999) 4540-4545
37. Davidson B., Lazarovici P., Ezersky A., et al. Expression levels of the NGF receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients. Clin Cancer Res 7 (2001) 3457-3464
38. Davidson B., Reich R., Lazarovici P., et al. Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma. Clin Cancer Res 9 (2003) 2248-2259
39. Davidson B., Reich R., Lazarovici P., et al. Altered expression and activation of the nerve growth factor receptors TrkA and p75 provides the first evidence of tumor progression to effusion in breast carcinoma. Breast Cancer Res Treat 83 (2004) 119-128
40. Davidson B., Reich R., Lazarovici P., et al. Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma. Lung Cancer 44 (2004) 159-165
41. Folkman J. Tumor angiogenesis. Adv Cancer Res 43 (1985) 175-203
42. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 82 (1990) 4-6
43. Fidler I.J., and Ellis L.M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79 (1994) 185-188
44. Folkman J., and Klagsbrun M. Angiogenic factors. Science 235 (1987) 442-447
45. Tischer E., Mitchell R., Hartman T., et al. The human gene for vascular endothelial growth factor. J Biol Chem 226 (1991) 11947-11954
46. Keck P.J., Hauser S.D., Krivi G., et al. Vascular permeability factor: an endothelial cell mitogen related to PDGF. Science 246 (1989) 1309-1312
47. Goldfarb M. The fibroblast growth factor family. Cell Growth Diff 1 (1990) 439-445
48. Gospodarowicz D., Neufeld G., and Schweigerer L. Molecular and biological characterization of fibroblast growth factor: an angiogenic growth factor which also controls the proliferation and differentiation of mesoderm and neuroectoderm derived cells. Cell Diff 19 (1986) 1-17
49. Koch A.E., Polverini P.J., Kunkel S.L., et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258 (1992) 1798-1801
50. Vlodavsky I., and Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 108 (2001) 341-347
51. Parish C.R., Freeman C., and Hulett M.D. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 1471 (2001) M99-M108
52. Kumar-Singh S., Weyler J., Martin M.J.H., et al. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGFβ expression. J Pathol 189 (1999) 72-78
53. Strizzi L., Catalano A Vianale G., et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 193 (2001) 468-475
54. Konig J., Tolnay E., Wiethege T., et al. Co-expression of vascular endothelial growth factor and its receptor flt-1 in malignant pleural mesothelioma. Respiration 67 (2000) 36-40
55. Konig J.E., Tolnay E., Wiethege T., et al. Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma. Virchows Arch 435 (1999) 8-12
56. Ohta Y., Shridhar V., Bright R.K., et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 81 (1999) 54-61
57. Catalano A., Romano M., Martinotti S., et al. Enhanced expression of vascular endothelial growth factor (VEGF) plays a critical role in the tumor progression potential induced by simian virus 40 large T cell antigen. Oncogene 21 (2002) 2896-2900
58. Davidson B., Vintman L., Zcharia E., et al. Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma. Clin Exp Metastasis 21 (2004) 469-476
59. Klominek J., Baskin B., and Hauzenberger D. Platelet-derived growth factor (PDGF) BB acts as a chemoattractant for human malignant mesothelioma cells via PDGF receptor beta-integrin alpha3beta1 interaction. Clin Exp Metastasis 16 (1998) 529-539
60. Ascoli V., Scalzo C.C., Facciolo F., et al. Platelet-derived growth factor receptor immunoreactivity in mesothelioma and nonneoplastic mesothelial cells in serous effusions. Acta Cytol 39 (1995) 613-622
61. Langerak A.W., De Laat P.A., Van Der Linden-Van Beurden C.A., et al. Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo. J Pathol 178 (1996) 151-160
62. Galffy G., Mohammed K.A., Dowling P.A., et al. Interleukin 8: an autocrine growth factor for malignant mesothelioma. Cancer Res 59 (1999) 367-371
63. Strizzi L., Vianale G., Catalano A., et al. Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival and angiogenesis. Int J Oncol 18 (2001) 1093-1098
64. Abulafia O., Triest W.E., and Sherer D.M. Angiogenesis in primary and metastatic epithelial ovarian carcinoma. Am J Obstet Gynecol 177 (1997) 541-547
65. Di Blasio A.M., Cremonesi L., Vigano P., et al. Basic fibroblast growth factor and its receptor messenger ribonucleic acids are expressed in human ovarian epithelial neoplasms. Am J Obstet Gynecol 169 (1993) 1517-1523
66. Davidson B., Goldberg I., Kopolovic J., et al. Expression of angiogenesis-related genes in ovarian carcinoma. A clinicopathologic study. Clin Exp Metastasis 18 (2000) 501-507
67. Boocock C.A., Charnock-Jones D.S., Sharkey A.M., et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 87 (1995) 506-516
68. Barton D.P.J., Cai A., Wendt K., et al. Angiogenic protein expression in advanced epithelial ovarian cancer. Clin Cancer Res 3 (1997) 1579-1586
69. Davidson B., Reich R., Kopolovic J., et al. Interleukin-8 and vascular endothelial growth factor mRNA levels are down-regulated in ovarian carcinoma cells in serous effusions. Clin Exp Metastasis 19 (2002) 135-144
70. Konstantinovsky S., Nielsen S., Vyberg M., et al. Angiogenic molecule expression is downregulated in effusions from breast cancer patients. Breast Cancer Res Treat 94 (2005) 71-80
71. Kleinman H.K., Koblinski J., Lee S., et al. Role of basement membrane in tumor growth and metastasis. Surg Oncol Clin North Am 10 (2001) 329-338
72. Hood J.D., and Cheresh D.A. Role of integrins in cell invasion and migration. Nat Rev 2 (2002) 91-100
73. Ruoslahti E. Integrins. J Clin Invest 87 (1991) 1-5
74. Sanders R.J., Mainiero F., and Giancotti F.P. The role of integrins in tumorigenesis and metastasis. Cancer Invest 16 (1998) 329-344
75. Menard S., Castronovo V., Tagliabue E., et al. New insights into the metastasis-associated 67 kD laminin receptor. J Cell Biochem 67 (1997) 155-165
76. Menard S., Tagliabue E., and Colnaghi M.I. The 67 kDa laminin receptor as a prognostic factor in human cancer. Breast Cancer Res Treat 52 (1998) 137-145
77. Givant-Horwitz V., Davidson B., and Reich R. Laminin-induced signaling in tumor cells: the role of the M(r) 67,000 laminin receptor. Cancer Res 64 (2004) 3572-3579
78. Klominek J., Sumitran Karupan S., and Hauzenberger D. Differential motile response of human malignant mesothelioma cells to fibronectin, laminin and collagen type IV: the role of β1 integrins. Int J Cancer 72 (1997) 1034-1044
79. Koukoulis G.K., Shen J., Monson R., et al. Pleural mestheliomas have an integrin profile distinct from visceral carcinomas. Hum Pathol 28 (1997) 84-90
80. Givant-Horwitz V., Davidson B., van de Putte G., et al. Expression of the 67kDa laminin receptor and the α6 integrin subunit in serous ovarian carcinoma. Clin Exp Metastasis 20 (2003) 599-609
81. Davidson B., Goldberg I., Reich R., et al. The αv and β1 integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients. Gynecol Oncol 90 (2003) 248-257
82. Sigstad E., Dong H.P., Nielsen S., et al. Quantitative analysis of integrin expression in effusions using flow cytometric immunophenotyping. Diagn Cytopathol 33 (2005) 321-331
83. Reich R., Vintman L., Nielsen S., et al. Differential expression of the 67 kilodalton laminin receptor in malignant mesothelioma and carcinomas that spread to serosal cavities. Diagn Cytopathol 33 (2005) 332-337
84. Egeblad M., and Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2 (2002) 161-174
85. Davidson B., Goldberg I., Gotlieb W.H., et al. High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis 17 (1999) 799-808
86. Davidson B., Reich R., Berner A., et al. Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels. Eur J Cancer 37 (2001) 2040-2049
87. Davidson B., Goldberg I., Berner A., et al. Expression of membrane-type 1,2 and 3 matrix metalloproteinases messenger RNA in ovarian carcinoma cells in serous effusions. Am J Clin Pathol 115 (2001) 517-524
88. Liu Z., and Klominek J. Regulation of matrix metalloprotease activity in malignant mesothelioma cell lines by growth factors. Thorax 58 (2003) 198-203
89. Harvey P., Clark I.M., Jaurand M.C., et al. Hepatocyte growth factor/scatter factor enhances the invasion of mesothelioma cell lines and the expression of matrix metalloproteinases. Br J Cancer 83 (2000) 1147-1153
90. Edwards J.G., McLaren J., Jones J.L., et al. Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura. Br J Cancer 88 (2003) 1553-1559
91. Moretta L., Biassoni R., Bottino C., et al. Human NK cells and their receptors. Microbes Infect 4 (2002) 1539-1544
92. Algarra I., Garcia-Lora A., Cabrera T., et al. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 53 (2004) 904-910
93. van der Ven K., Pfeiffer K., and Skrablin S. HLA-G polymorphisms and molecule function- questions and more questions: a review. Placenta 21 (2000) S86-S92 (suppl A)
94. Hofmeister V., and Weiss E.H. HLA-G modulates immune responses by diverse receptor interactions. Semin Cancer Biol 13 (2003) 317-323
95. Brostjan C., Bellon T., Sobanov Y., et al. Differential expression of inhibitory and activating CD94/NKG2 receptors on NK cell clones. J Immunol Methods 264 (2002) 109-119
96. McMaster M.T., Librach C.L., Zhou Y., et al. Human placental HLA-G expression is restricted to differentiated cytotrophoblasts. J Immunol 154 (1995) 3771-3778
97. McMaster M., Zhou Y., Shorter S., et al. HLA-G isoforms produced by placental cytotrophoblasts and found in amniotic fluid are due to unusual glycosylation. J Immunol 160 (1998) 5922-5928
98. Paul P., Rouas-Freiss N., Khalil-Daher I., et al. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci USA 95 (1998) 4510-4515
99. Urosevic M., Willers J., Mueller B., et al. HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood 99 (2002) 609-617
100. Singer G., Kurman R.J., McMaster M., et al. HLA-G immunoreactivity is specific for intermediate trophoblast in gestational trophoblastic disease and can serve as a useful marker in differential diagnosis. Am J Surg Pathol 26 (2002) 914-920
101. Bukur J., Rebmann V., Grosse-Wilde H., et al. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res 63 (2003) 4107-4111
102. Urosevic M., Kurrer M.O., Kamarashev J., et al. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol 159 (2001) 817-824
103. Lefebvre S., Antoine M., Uzan S., et al. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J Pathol 196 (2002) 266-274
104. Singer G., Rebmann V., Chen Y.C., et al. HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res 9 (2003) 4460-4464
105. Davidson B., Bukholt Elstrand M., McMaster M.T., et al. HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. Gynecol Oncol 96 (2005) 42-47
106. Kleinberg L., Florenes V.A., Skrede M., et al. Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. Virchows Arch 449 (2006) 31-39
107. Dong H.P., Bunkholt Elstrand M., Holth A., et al. NK and B cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. Am J Clin Pathol 125 (2006) 451-458
108. Denhardt D.T. Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signalling. Biochem J 318 (1996) 729-747
109. Garrington T.P., and Johnson G.L. Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol 11 (1999) 211-218
110. Fanger G.R. Regulation of the MAPK family members: role of subcellular localization and architectural organization. Histol Histopathol 14 (1999) 887-894
111. Chang L., and Karin M. Mammalian MAP kinase signalling cascades. Nature 410 (2001) 37-40
112. Davis R.J. MAPKs: new JNK expands the group. Trends Biochem Sci 19 (1994) 470-473
113. Givant-Horwitz V., Davidson B., Lazarovici P., et al. Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions. Gynecol Oncol 91 (2003) 160-172
114. Givant-Horwitz V., Davidson B., Goderstad J.M., et al. The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma. Gynecol Oncol 93 (2004) 517-523
115. Vintman L., Nielsen S., Berner A., et al. Mitogen-activated protein kinase expression and activation does not differentiate benign from malignant mesothelial cells. Cancer 103 (2005) 2427-2433